Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study to Investigate the Safety and Biodistribution of a Single Intrathecal Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (The ASCEND Study)

NCT06817382 is registered in ClinicalTrials.gov with Insmed Gene Therapy LLC as lead sponsor.

NCT NCT06817382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06817382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study to Investigate the Safety and Biodistribution of a Single Intrathecal Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (The ASCEND Study)
Lead sponsor
Insmed Gene Therapy LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 22, 2025
Completion date
March 31, 2028
Enrollment
12 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy